Please assess the completion status of the following clinical trial:

Trial Title: Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:~  * Primary refractory disease (no complete response \[CR\] after ≥ 2 induction therapies)~ * Relapsed disease not in CR after ≥ 1 course of standard reinduction therapy~ * Secondary AML from myelodysplastic syndromes~ * Disease relapsed ≥ 2 months after transplant and no option of donor lymphocyte infusions (e.g., recipients of autologous or umbilical cord blood transplants)~ * Chronic myelogenous leukemia with myeloid blast crisis not in second chronic phase after at least one cycle of standard chemotherapy and imatinib~ * Over 60 years of age with relapse within 6 months after completion of last chemotherapy~ * Over 60 years of age with blast count \< 30% within 10 days before study entry~* Related HLA-haploidentical natural killer cell donor available~* No severe organ damage (by clinical or laboratory assessment)~* Performance status 50-100%~* No evidence of active infection on chest X-ray~* No active fungal infection~Exclusion Criteria:~* Active central nervous system (CNS) leukemia~* Pleural effusions large enough to be detectable by chest x-ray~* Pregnant or nursing (positive pregnancy test)~* Fertile patients must use effective contraception~* Less than 60 days since prior transplant~* Less than 3 days since prior prednisone~* Less than 3 days since other prior immunosuppressive medication

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intent-to-Treat (Type: EXPERIMENTAL): All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10\^7/kg.)

Based on this trial design, predict the completion outcome and termination type (if applicable).